Objetivo
Previous well-publicised studies of thrombolysis in patients with suspected acute myocardial infarction have suggested that the sooner treatment is administered, the greater the benefit in terms of reduced mortality. Pre-hospital thrombolysis has been advocated as a way of treating more patients earlier EMIP (European Myocardial Infarction Project) is a large-scale randomised study which was set up and sponsored by the European Economic Community through its Medical Research Program to assess the risks and benefits of such an approach
To determine the theoretical risk/benefit ratio of prehospital thrombolytic treatment, the European Myocardial Infarction Project (EMIP) was established. In a double blind, randomised trial, prehospital thrombolysis was compared with in hospital treatment. Anistreplase was the chosen thrombolytic agent because, being administered as a bolus, it is suitable for a prehospital setting. The study involved 5469 patients who received either 30 units of anistreplase at home followed by placebo after hospital admission, or placebo at home followed by 30 units of anistreplase after hospital admission. In 92.4% of cases, the diagnosis of suspected myocardial infarction was confirmed by the hospital cardiologist. Minor adverse reactions were more frequent in the early treatment group but the incidence of severe adverse reactions such as cerebral bleeding, ischaemicstrokes and severe bleeding was similar in both groups. As severe bleeding was among the main concerns expressed about prehospital thrombolysis, it is important to note that there was no occurrence of severe bleeding before admission and only one after admission, prior to the second injection. The frequency of reinfarction, ventricular fibrillation, acute pulmonary oedema, shock and cardiac arrest was the same in both groups. A total of 569 deaths was observed at 30 days, mortality being 13% lower in the early treatment group. The risk ratio decreased with increasing time gained by early treatment (the interval between injections). Death from cardiac causes was 16% lower in the early treatment arm, the result being at the limit of statistical significance (p=0.049). EMIP has thus proved prehospital thrombolysis to be feasible and safe, with no more incorrect diagnosis of myocardial infarction than in hospital, provided that the teams are well equipped and staffed.
A pilot study, sponsored by the EEC showed that a gain of one to two hours could be expected from a pre-hospital strategy with pre-hospital administration of a thrombolytic agent, compared with the current hospital strategy.
The primary objective of this study was to evaluate the benefit/risk ratio of administering a thrombolytic agent to patients with suspected myocardial infarction as early as possible after the onset of symptoms in a pre-hospital setting. Anistreplase was chosen because it can be administered as a slow bolus. Patients were randomised to receive anistreplase either as a pre-hospital treatment or after hospital admission, but this comparison goes beyond that of a simple comparison of two treatments, it is a comparison of two treatment strategies involving different settings and staff with different backgrounds. The evaluation of all aspects of safety of the two strategies is, therefore, of utmost importance.
Ámbito científico (EuroSciVoc)
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
Para utilizar esta función, debe iniciar sesión o registrarse
Programa(s)
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Tema(s)
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Convocatoria de propuestas
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Datos no disponibles
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Régimen de financiación
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Coordinador
69394 Lyon
Francia
Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.